Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | CTSS | P25774 | 7/20 | 0.57 |
| ▸ | CTSK | P43235 | 6/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956884 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL29401155 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL30082858 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL3817907 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL15856094 | 0.90 | CTSS (0.55) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL15856124 | 0.90 | CTSS (0.55) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL2352344 | 0.89 | KLK5 (0.59) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL6491302 | 0.89 | KLK5 (0.59) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL2352336 | 0.89 | KLK5 (0.59) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL29543144 | 0.89 | KLK5 (0.59) | ACECTSSCTSKCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| CN-117715658-A | Method for inhibiting RAS | 锐新医药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| CN-117616031-A | RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2024035871-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240043470-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | UNIV CORNELL (US) | 2024-02-08 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
| US-6362165-B1 | Hydroxyphenyl derivatives with HIV integrase inhibitory properties | PHARMACOR INC. (CA) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | ACE 87/4885CTSS 468/4885CTSK 1005/4885 |
| US-20240043470-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB3 | ACE 1331/4885CTSS 640/4885CTSK 1101/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | ACE 1211/4885CTSS 2141/4885CTSK 1705/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | ACE 1331/4885CTSS 640/4885CTSK 1101/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | ACE 1331/4885CTSS 640/4885CTSK 1101/4885 |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | ACE 2157/4885CTSS 1730/4885CTSK 932/4885 |
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | ACE 1332/4885CTSS 1158/4885CTSK 1629/4885 |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | NME2, BTD, BLVRB | ACE 4079/4885CTSS 1784/4885CTSK 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.